Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for GTX-102 in Angelman Syndrome. The expected timing is based on the latest available company guidance and may change.
ASPIRE, Aurora trials. 7/17/24- Alignment w/ FDA on Ph3 study endpoints. 12/19/24- First patient dosed in ASPIRE trial. 7/31/25- ASPIRE trial enrollment completed. 10/30/25- First patient dosed in Aurora study. Data from Aspire study in H2 2026. 11/04/25:- Reiterated ASPIRE Ph3 fully enrolled; Aspire Ph3 data expected H2 2026. 01/12/26:- Reiterated ASPIRE Ph3 fully enrolled; Aspire Ph3 pivotal data expected H2 2026; Aurora Ph2/3 ongoing. 05/05/26:- New long-term Ph1/2 data show durable multdomain improvement, stable safety; ASPIRE Ph3 data and Aurora enrollment expected H2 2026. 08/04/26:- Aspire Ph3 data expected September or October; Aurora enrollment completion expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.